Preoperative Risk Classification Using Neutrophil-to-Lymphocyte Ratio and Albumin for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

被引:5
|
作者
Zhao, Zihan [1 ]
Xie, Shangxun [1 ]
Feng, Baofu [1 ]
Zhang, Shiwei [1 ]
Sun, Yifan [1 ]
Guo, Hongqian [1 ]
Yang, Rong [1 ]
机构
[1] Nanjing Univ, Med Sch, Inst Urol, Dept Urol,Nanjing Drum Tower Hosp,Affiliated Hosp, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
neutrophil-to-lymphocyte ratio; albumin; upper tract urothelial carcinoma; radical nephroureterectomy; risk classification; UPPER URINARY-TRACT; SYSTEMIC INFLAMMATORY RESPONSE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTOR; HYPOALBUMINEMIA; BLADDER;
D O I
10.2147/CMAR.S274332
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To improve the preoperative prediction of the outcomes of patients diagnosed with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU), we explored various preoperative laboratory factors and established a prognostic risk stratification method. Patients and Methods: We retrospectively reviewed 232 UTUC patients who underwent RNU from September 2010 to October 2019 and analyzed their comprehensive clinicopathologic data and preoperative blood-based biomarkers. Kaplan-Meier analysis, receiver operating characteristic (ROC) curves analysis and Cox regression analysis were performed to assess the relationship between these factors and the prognosis. Results: The median follow-up and age were 24 months and 68.5 years, respectively. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR 3.44) and decreased albumin (ALB < 39.8 g/L) were negatively correlated with progression-free survival (PFS), cancer specific survival (CSS) and overall survival (OS) in both univariate and multivariate analyses. Patients were sorted into three groups based on their NLR and ALB: the low-risk group (neither elevated NLR nor decreased ALB), intermediate-risk group (either elevated NLR or decreased ALB) and high-risk group (elevated NLR and decreased ALB). Their 5-year PFS rates were 77.8%, 52.6% and 32.3%; their 5-year CSS rates were 97.7%, 71.4% and 32.9%; and their 5-year OS rates were 92.7%, 70.4% and 29.2%, respectively (all P < 0.0001). ROC curves analysis showed that NLR plus ALB had a more accurate prognostic value (P < 0.05). Conclusion: Preoperative risk classification using NLR and ALB was identified as an independent prognostic factor for patients with UTUC. The combination of NLR and ALB may help to determine the most appropriate treatment options before RNU.
引用
收藏
页码:9023 / 9032
页数:10
相关论文
共 50 条
  • [31] Predictive value of preoperative lymphocyte-to-monocyte ratio for patients with upper tract urothelial carcinoma
    Li, Tao
    Xu, Hang
    Yang, Lu
    Tan, Ping
    Wei, Qiang
    CLINICA CHIMICA ACTA, 2019, 492 : 50 - 56
  • [32] Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma
    Cao Zhen-Peng
    Guan Bao
    Zhao Guang-Zhi
    Fang Dong
    Xiong Geng-Yan
    Li Xue-Song
    Zhou Li-Qun
    中华医学杂志英文版, 2016, 130 (17) : 2063 - 2068
  • [33] Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma
    Singla, Nirmish
    Hutchinson, Ryan
    Haddad, Ahmed
    Sagalowsky, Arthur
    Lotan, Yair
    Margulis, Vitaly
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (04) : 8334 - 8341
  • [34] Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Choi, Han-Yong
    Lee, Hyun Moo
    BJU INTERNATIONAL, 2015, 115 (04) : 587 - 594
  • [35] Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma
    Lee, Byron H.
    Zabor, Emily C.
    Tennenbaum, Daniel
    Furberg, Helena
    Benfante, Nicole
    Coleman, Jonathan A.
    Jaimes, Edgar A.
    Russo, Paul
    WORLD JOURNAL OF UROLOGY, 2018, 36 (02) : 257 - 263
  • [36] A critical prognostic analysis of neutrophil–lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma
    Mesut Altan
    Hakan Bahadır Haberal
    Bülent Akdoğan
    Haluk Özen
    International Journal of Clinical Oncology, 2017, 22 : 964 - 971
  • [37] Preoperative C-Reactive Protein in the Serum: A Prognostic Biomarker for Upper Urinary Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
    Aziz, Atiqullah
    Rink, Michael
    Gakis, Georgios
    Kluth, Luis A.
    Dechet, Christopher
    Miller, Florian
    Otto, Wolfgang
    Gierth, Michael
    Denzinger, Stefan
    Schwentner, Christian
    Stenzl, Arnulf
    Fisch, Margit
    Burger, Maximilian
    Fritsche, Hans-Martin
    UROLOGIA INTERNATIONALIS, 2014, 93 (03) : 352 - 360
  • [38] Influence of tumour location on the survival outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy
    Kang Liu
    David Ka-Wai Leung
    Chris Ho-Ming Wong
    Ivan Ching-Ho Ko
    Rahim Horuz
    Paolo Gontero
    Pilar Laguna
    Jean de la Rosette
    Jeremy Yuen-Chun Teoh
    World Journal of Urology, 43 (1)
  • [39] Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy
    Huang, Jiwei
    Wang, Yanqing
    Yuan, Yichu
    Chen, YongHui
    Kong, Wen
    Chen, Haige
    Zhang, Jin
    Huang, Yiran
    ONCOTARGET, 2017, 8 (22) : 36772 - 36779
  • [40] Prognostic impact of postoperative neutrophil-to- lymphocyte ratio on survival outcomes of patients treated with radical nephroureterectomy for upper urinary tract urothelial carcinoma: a single institution retrospective analysis using propensity score matching
    Kim, Hyung Suk
    Lee, Hui Seung
    Ku, Ja Hyeon
    JOURNAL OF CANCER, 2023, 14 (07): : 1174 - 1181